PLSE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pulse Biosciences Inc (PLSE) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has positive technical indicators and bullish analyst ratings, the company's financial performance is weak, with declining net income and EPS. Additionally, insider selling activity has significantly increased, which raises concerns about confidence in the stock. The lack of recent news catalysts and no significant trading signals further supports a hold recommendation.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone, and moving averages indicating upward momentum (SMA_5 > SMA_20 > SMA_200). The pre-market price is near the R1 resistance level of 24.16, suggesting limited immediate upside potential.
Bullish analyst ratings with increased price targets from Oppenheimer and Mizuho, citing strong product potential and FDA approval for pivotal IDE study.
Encouraging feasibility study data for the nPulse Cardiac Catheter.
Significant insider selling activity, with a 3340.02% increase in the last month.
Weak financial performance in Q4 2025, with declining net income (-10.07% YoY) and EPS (-16.13% YoY).
No recent news or significant trading trends to drive short-term momentum.
In Q4 2025, revenue remained flat at $264,000 YoY. Net income dropped to -$17.43M (-10.07% YoY), and EPS declined to -0.26 (-16.13% YoY). Gross margin remained unchanged at 1.52%. The financials indicate weak growth and profitability trends.
Analysts are bullish on PLSE, with Oppenheimer and Mizuho raising price targets to $30 and maintaining Outperform ratings. The positive outlook is driven by strong product potential and FDA approval for a pivotal IDE study.
